Difunctional dendritic lipopeptide nano-micelle as well as preparation method and application thereof

By simplifying the synthesis and purification process, the fourth generation of glutamate dendrimers combines ROS response bonds to form bifunctional dendrimer nanomicrobes, solving the complexity and application limitations of chiral dendrimer synthesis in the prior art. The problem of this paper has achieved efficient autophagy induction and ROS clearance of inflammatory immune cells, and expanded the scope of treatment application.

CN118924682AActive Publication Date: 2024-11-12CHINA PHARM UNIV
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202410936368.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-12
Estimated Expiration
2044-07-12

AI Technical Summary

Technical Problem

The prior art has a long process of preparation and purification when synthesizing chiral dendrimers, and is mainly used to induce autophagy of tumor cells. It lacks the effect on inflammatory immune cells, and the types of amino acids used are single, so the verification effect is limited.

Method used

Innovatively prepared the fourth generation of glutamate dendrimers, and by changing the hydrophobic long chain structure and connecting the ROS response bonds, forming bifunctional dendritic lipopeptide nanomicrobes, simplifying the synthesis and purification process, which can be used in inflammation. Autophagy of macrophages is induced in the environment and drug is released through ROS response.

Benefits of technology

It has achieved low toxicity, ROS responsiveness and efficient autophagy induction effects, expanding the application prospects of treatment, especially in an inflammatory environment, which can effectively eliminate excessive ROS and reduce oxidative stress and inflammatory response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924682A_ABST
    Figure CN118924682A_ABST
Patent Text Reader

Abstract

The invention relates to a difunctional dendritic lipopeptide nano-micelle as well as a preparation method and application thereof, and belongs to the technical field of medicines. On the basis of a fourth-generation lysine chiral molecule, the hydrophobic tail chain structure of the fourth-generation lysine chiral molecule is changed, and an ROS response bond is connected, so that the fourth-generation glutamic acid dendrimer has low toxicity and ROS responsiveness, and the fourth-generation glutamic acid dendrimer is innovatively prepared and has the effect of inducing autophagy. On the basis, the dendritic lipopeptide nano-micelle D-RNPs with double functions of ROS response and autophagy induction is provided. Two four-generation dendrimers (lysine and glutamic acid) are creatively mixed and self-assembled into the dendritic lipopeptide nano-micelle, the hydrophobic long-chain structure of the four-generation lysine dendrimers is changed, and an ROS response bond (TK) is added, so that the dendritic lipopeptide nano-micelle has low toxicity and ROS responsiveness. In the aspect of activating autophagy, the expression of two proteins P63 and LC3 is verified through an immune protein experiment, and compared with the prior art, the autophagy effect is better, and meanwhile, the ROS responsiveness is good.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a bifunctional dendritic lipopeptide nano-micelle and a preparation method and application thereof, belonging to the technical field of medicines. Background Art

[0002] Oxidative stress refers to a state in which the body's oxidation and anti-oxidation are out of balance and tend to be oxidative. This state is caused by excessive production of reactive oxygen species (ROS) and decreased antioxidant capacity of the body. ROS include superoxide anions (O2 – Oxidative chemicals such as hydroxyl radicals (·OH), hydrogen peroxide (H2O2), and hydroxyl radicals (·OH) are normal products of cell metabolism and participate in cell signal transduction and biological regulation at normal levels. When the production of ROS exceeds the clearance capacity of the body's antioxidant system, oxidative stress will occur, causing damage to cells and tissues. By supplementing antioxidants, reducing ROS production, or enhancing ROS clearance capacity, it is expected to provide new ideas for the treatment of various inflammatory diseases.

[0003] Autophagy can clear the accumulated lipids, damaged organelles and protein aggregates in cells, thereby preventing the accumulation of these harmful substances from causing further damage to cells. This cleaning effect helps to reduce stress and inflammatory responses in cells. Dysregulation of autophagy may lead to cell apoptosis and senescence, and promote the infiltration of inflammatory cells. In summary, autophagy, an intracellular cleaning and recycling mechanism, plays an important role in maintaining the homeostasis and function of vascular cells. Autophagy can degrade and reuse damaged or aged organelles and proteins, which has positive significance for preventing the accumulation of harmful substances and reducing stress and inflammatory responses.

[0004] In this context, dendritic lipopeptides, as a new type of biomolecule that combines the characteristics of dendritic molecules and lipopeptides, have brought new hope for regulating intracellular inflammatory responses and activating autophagy with their unique structural and functional properties. Dendritic lipopeptides combine the highly branched structure of dendritic molecules with the biological activity of lipopeptides to form a stable three-dimensional structure. Its hydrophilic head and hydrophobic tail together constitute a unique amphiphilic structure, which enables dendritic lipopeptides to form complex nanostructures such as nanofibers, nanotubes, vesicles, etc. through molecular self-assembly. These characteristics not only give dendritic lipopeptides special physical and chemical properties, but also enable them to show great application potential in the fields of drug delivery and bioimaging.

[0005] Autophagy is considered a key process for maintaining cellular homeostasis and a response to stressors such as nutrient deprivation, which may jeopardize cell survival. When cells are exposed to these stressors, autophagy, which occurs at low levels to balance the constant synthesis of biomolecules, is greatly upregulated. This upregulation increases the absorption and degradation of cells, releasing macromolecules back into the cytoplasm to drive essential metabolic reactions and generate energy. In fact, autophagy has been found to be useful during mammalian development, and recent studies have found that autophagy is an important regulator of various diseases and conditions. Among them, rapamycin, as the most classic autophagy inducer targeting mTOR, has been widely used, but its side effects have been found to be dose-dependent and reversible in a large number of clinical trials. The main toxic and side effects include headache, nausea, dizziness, nosebleeds, joint pain, etc., with large side effects.

[0006] Many existing technologies also use amino acids such as lysine to synthesize chiral dendrimer structures, but the preparation and purification process is relatively long. In addition, the existing dendrimers composed of chiral amino acids of more than three generations have been found to induce autophagy in different tumor cells, but not in immune cells. Moreover, most of the existing technologies are simple synthetic chiral dendrimer structures, and the amino acids used are mostly lysine and arginine, and only one of them has been verified.

[0007] Based on the above situation, the present invention is proposed. Summary of the invention

[0008] The purpose of the present invention is to overcome the shortcomings of the prior art. Based on the fourth-generation lysine chiral molecule, the hydrophobic tail chain structure is changed, and a ROS response bond is connected to make it have low toxicity and ROS responsiveness. The fourth-generation glutamate dendrimer is innovatively prepared, and has the effect of inducing autophagy. On this basis, a dendritic lipopeptide nano-micelle with dual functions of ROS response and inducing autophagy is provided. D -RNPs. Another object of the present invention is to provide a dual-functional nano-micelle D -RNPs preparation method and in vitro application.

[0009] In view of the problem that the preparation and purification process of the chiral dendrimer structure synthesized in the prior art is relatively long, the present invention simplifies the synthesis and purification process while improving the synthesis yield, and changes the hydrophobic long chain structure, and connects the ROS response bond to the original chiral structure, so that the synthesized product has low toxicity and ROS responsiveness. In the existing dendrimers composed of chiral amino acids of more than three generations, it has been found that most of them induce autophagy of different tumor cells. The present invention further explores that inflammatory immune cells (such as macrophages) can also be induced to occur autophagy, so that the cell level does not only stay on special tumor cells, and the prospects for therapeutic applications are broader.

[0010] With regard to the existing technologies, most of which are simple synthetic chiral dendrimer structures, and the amino acids used are mostly lysine and arginine, and only one of the verified effects is used, the present invention innovatively synthesizes the fourth generation of dendrimers prepared from glutamic acid, and the synthesis and purification processes are relatively simplified. At the same time, two different dendrimers are innovatively mixed and self-assembled in an equimolar ratio to form dendrimer lipopeptide nano-micelles, which have two effects, ROS response and induction of autophagy. The two effects synergistically treat in an inflammatory environment, and have great application potential.

[0011] The technical solution of the present invention is as follows:

[0012] In the first aspect of the present invention, a bifunctional dendritic lipopeptide nano-micelle is proposed and prepared for the first time, which is made of chiral ROS-responsive dendritic lipopeptide KRDL and glutamic acid dendritic lipopeptide molecule EDL as raw materials.

[0013] The structural formula of KRDL is shown in Formula I:

[0014]

[0015] in:

[0016] R1 is a dendrimer polypeptide composed of amide bonds between lysines in a certain ratio, and the structure of R1 is shown in Formula II:

[0017]

[0018] In formula II, n represents D-lysine, and a tree network is formed by amide bonds;

[0019] R2 is a carbon chain C containing a TK bond 27 H 50 O2NS2:

[0020] The structure of the EDL is shown in Formula III:

[0021]

[0022] in:

[0023] R3 is a dendrimer polypeptide composed of glutamic acids in a certain ratio through amide bonds, and the structure of R3 is shown in Formula IV:

[0024]

[0025] In formula IV, n represents glutamic acid, and a tree network is formed by amide bonds;

[0026] R4 is a carbon chain C 18 H 33 O.

[0027] In the present invention, KRDL consists of two parts, a hydrophobic tail and a hydrophilic head. The hydrophobic tail is a hydrophobic long chain composed of ROS-responsive bonds thioketal and oleylamine, wherein the ROS-responsive bond refers to a TK bond that can respond to the higher ROS concentration in the plaque site to break and release the drug; the hydrophilic head is an amphiphilic polypeptide formed by amide bonds between lysines in a certain proportion. EDL consists of two parts, a hydrophobic tail and a hydrophilic head. The hydrophobic tail is a hydrophobic long chain composed of oleic acid, and the hydrophilic head is an amphiphilic polypeptide formed by amide bonds between glutamic acids in a certain proportion. After KRDL and EDL are mixed in an equimolar ratio, they can self-assemble into nano-micelles in the solution according to the hydrophilic heads and hydrophobic tails of the two. KRDL contains the ROS-responsive bond TK, which can spontaneously break in an inflammatory environment, and the D-type can effectively prevent the degradation of enzymes in the body compared with the L-type, thereby releasing more EDL dendrimers and D-type lysine dendrimers in an inflammatory environment, inducing macrophage autophagy.

[0028] Furthermore, the dendritic lipopeptide nano-micelles are prepared by mixing chiral ROS-responsive dendritic lipopeptide KRDL and glutamic acid dendritic lipopeptide molecules EDL in an equimolar ratio through a solvent injection method.

[0029] Furthermore, the structures of KRDL and EDL in the preferred bifunctional dendritic lipopeptide nanomicelles of the present invention are as follows:

[0030] The structure of KRDL is shown in Formula V:

[0031]

[0032] The structure of EDL is shown in Formula VI:

[0033]

[0034] In the second aspect of the present invention, a method for preparing the bifunctional dendritic lipopeptide nanomicelles as described in the first aspect is provided.

[0035] The method for preparing the bifunctional dendritic lipopeptide nanomicelles comprises the following steps:

[0036] (1) Synthetic G n K(n=2,3,4)

[0037] Synthesis of chiral dendrimers G with different generations based on D-lysine as the basic structural unit n K(Boc)(n=2,3,4), and further remove the Boc protecting group to obtain the corresponding chiral dendrimer product G n K(n=2,3,4);

[0038] (2) Synthesis of chiral ROS-responsive dendritic lipopeptide KRDL

[0039] Based on the fourth generation chiral lysine molecule, a demethylation reaction was performed with a sodium hydroxide methanol solution (1 mol / L) to expose the carboxyl group, extracted with ethyl acetate, dried with anhydrous Na2SO4, evaporated and concentrated under reduced pressure to remove the solvent, and vacuum dried for 24 hours to obtain a series of intermediates, which were then joined with a hydrophobic long chain consisting of ROS-responsive bond ketalthiols and oleylamine to synthesize a chiral ROS-responsive dendritic lipopeptide. D -KRDL;

[0040] (3) Synthesis of glutamate dendritic lipopeptide molecules EDL

[0041] Synthesize dendrimers of different generations with glutamic acid as the basic structural unit. On the basis of the fourth-generation glutamic acid molecule, further remove the Fmoc protecting group and then connect the hydrophobic long chain composed of oleic acid to synthesize the glutamic acid dendrimer lipopeptide molecule EDL.

[0042] (4) Preparation of Nanomicelles

[0043] Will D -KRDL and EDL were mixed in a 1:1 molar ratio, added to a 1:1 volume ratio of anhydrous ethanol and tetrahydrofuran to fully dissolve them, and then added dropwise to a rapidly stirred PBS solution at a uniform speed, and stirred until the anhydrous ethanol and tetrahydrofuran were completely volatilized to form nanomicelles. D -RNPs.

[0044] Furthermore, in the step (1), the second generation chiral dendrimer D -The synthesis method of G2K is as follows:

[0045] 1) In an ice bath and under nitrogen protection, the above raw materials are added to a reaction device according to the molar ratio of DH-Lys-OMe·2HCl, Boc-Lys(Boc)-OH, HOBT, HBTU, and DIPEA being 1:2:3:3:6, and then appropriate amounts of DMF and DIPEA are added to dissolve the solid drug, and the reaction is first carried out in an ice bath for 30 minutes, and then stirred at room temperature for 24 hours. After the reaction is completed, the reaction solution is extracted, washed, salted out, and dried to obtain a crude product solution, and then the crude reaction solution is concentrated and purified to obtain D -G2K(Boc)4;

[0046] 2) Take the above D -G2K(Boc)4 was placed in a reaction apparatus, and DCM was slowly added to dissolve it under nitrogen protection, and then TFA was slowly added. The reaction was stirred in an ice bath for 30 minutes, and the reaction was continued at room temperature for 3-6 hours. After the reaction was completed, the reaction solution was evaporated and concentrated to dryness under reduced pressure, washed, and vacuum dried for 24 hours to obtainD -G2K; D -The weight volume ratio of G2K(Boc)4, DCM and TFA is: 1 g: 3 mL: 3 mL.

[0047] Furthermore, in the step (1), the third generation chiral dendrimer D The synthesis method of -G3K is as follows:

[0048] 1) In an ice bath and under nitrogen protection, D -G2K, Boc-D-Lys(Boc)-OH, HOBT, HBTU, DIPEA in a molar ratio of 1:4:5:5:11, the above raw materials are added to a reaction device, and then appropriate amounts of DMF and DIPEA are added to dissolve the solid drug, first react in an ice bath for 30 minutes, and then react under stirring at room temperature for 24 hours; after the reaction is completed, the reaction solution is extracted, and washed, salted out, and dried to obtain a crude product solution, and the organic phase is concentrated by reduced pressure evaporation after suction filtration, and then recrystallized, filtered and crystallized, filtered to dryness, and vacuum dried for 24 hours to obtain D -G3K(Boc)8;

[0049] 2) Weigh the above D -G3K(Boc)8 in a reaction device, under nitrogen protection, slowly add a mixed solvent of TFA and DCM to the above reaction device, under nitrogen protection, stir the reaction in an ice bath for 30 minutes, and continue to stir the reaction at room temperature for 4-6 hours; after the reaction is completed, evaporate the reaction solution under reduced pressure and concentrate it to dryness, wash it, and vacuum dry it for 24 hours to obtain D -G3K; among them D -The weight volume ratio of G3K(Boc)8, TFA and DCM is: 2g:7mL:7mL.

[0050] Furthermore, in the step (1), the fourth generation chiral dendrimer D The synthesis method of -G4K is as follows:

[0051] 1) In an ice bath and under nitrogen protection, D -G3K, Boc-D-Lys(Boc)-OH, HOBT, HBTU, DIPEA in a molar ratio of 1:10:12:12:30, add the above raw materials into a reaction device, add appropriate amounts of DMF and DIPEA to dissolve the solid drug, first react in an ice bath for 30 minutes, then stir and react at room temperature for 36 hours, after the reaction is completed, extract the reaction solution, wash, salt out, and dry to obtain a crude product solution, filter and concentrate the organic phase by reduced pressure evaporation, then recrystallize, filter and crystallize, filter to dryness, and then vacuum dry for 24 hours to obtain D -G4K(Boc) 16 ;

[0052] 2) Weigh the above D -G4K(Boc) 16 In a reaction apparatus, under nitrogen protection, a mixed solvent of TFA and DCM was slowly added to the above reaction apparatus, and the reaction was stirred in an ice bath under nitrogen protection for 30 minutes, and the reaction was continued to be stirred at room temperature for 5-7 hours. After the reaction was completed, the reaction solution was evaporated and concentrated to dryness under reduced pressure, washed, and vacuum dried for 24 hours to obtain D -G4K; D -G4K(Boc) 16 , the weight volume ratio of TFA and DCM is: 1g:4mL:4mL.

[0053] Furthermore, in the step (2), the synthesis method of the chiral ROS-responsive dendritic lipopeptide KRDL is as follows:

[0054] (1) Take D -G4K(Boc) 16 In the reaction apparatus, sodium hydroxide methanol solution was added and the reaction was carried out under ice bath for 8 hours. After the reaction was completed, the pH of the reaction solution was adjusted to 3-4 with hydrochloric acid solution, and the reaction solution was extracted with ethyl acetate 3 times. The organic phase was collected, anhydrous Na2SO4 was added for drying, and the solvent was removed by vacuum evaporation after filtration. The product was dried in vacuo for 24 hours to obtain D -Compoud 1;

[0055] (2) In an ice bath and under nitrogen protection, according to Fmoc-ethylenediamine, D -Compoud 1, HOBT, HBTU and DIPEA have a molar ratio of 1:1:1.2:1.2:8. The above raw materials are added to a reaction device, and DMF and DIPEA are added to dissolve the solid drug. The reaction is first carried out in an ice bath for 30 minutes, and then stirred at room temperature for reaction. After the reaction is completed, the reaction solution is extracted, washed, salted out, and dried to obtain a crude product solution. After suction filtration, the organic phase is evaporated and concentrated under reduced pressure, and then recrystallized. The crystals are suction filtered, and after suction filtration to dryness, vacuum drying is performed for 24 hours to obtain D -Compoud 2;

[0056] (3) Take D -Compoud 2 was placed in a reaction device, and under nitrogen protection, a mixed solvent of piperidine and DMF with a volume ratio of 1:4 was slowly added. Under nitrogen protection, the mixture was stirred in an ice bath for 30 minutes, and the mixture was stirred at room temperature for 6 hours. After the reaction was completed, the reaction solution was transferred to another reaction device, anhydrous ethanol was added, and the mixture was evaporated and concentrated under reduced pressure. The operation was repeated until there was no piperidine on the plate. After the piperidine was cleaned, the mixture was evaporated and concentrated under reduced pressure and dried, and vacuum dried for 24 hours to obtain D -Compoud 3; among them, D-The weight volume ratio of Compoud 2 to the mixed solvent of piperidine and DMF is: 0.22 g: 5 mL;

[0057] (4) Under ice bath and nitrogen protection, D -Compoud 3, TK-OAm, HOBT, HBTU, DIPEA in a molar ratio of 1:1.2:1.3:1.3:10, add the above raw materials into a reaction device, then add DMF and DIPEA to dissolve the solid drug, first react in an ice bath for 30 minutes, then stir and react at room temperature, after the reaction is completed, extract the reaction solution, wash, salt out, and dry to obtain a crude product solution; after suction filtration, evaporate and concentrate the organic phase under reduced pressure, then recrystallize, filter the crystals, filter to dryness, and vacuum dry for 24 hours to obtain D -Compoud4;

[0058] (5) Take D -Compoud4 was placed in a reaction device, and under nitrogen protection, a mixed solution of TFA and DCM in a volume ratio of 1:3 was slowly added to the above reaction device. Under nitrogen protection, the reaction was stirred in an ice bath for 30 minutes, and the reaction was continued at room temperature for 6-8 hours. After the reaction was completed, the reaction solution was evaporated and concentrated to dryness under reduced pressure, washed, and vacuum dried for 24 hours to obtain D -KRDL; among them, D -The weight volume ratio of the mixed solution of Compoud 4 and TFA and DCM is: 0.2 g:8 mL.

[0059] Furthermore, in the step (2), the method for synthesizing the carbon chain TK-OAm containing a TK bond is as follows: in an ice bath and under nitrogen protection, the above raw materials are added to a reaction device according to a molar ratio of TK, OAm, EDCI, and NHS of 1:2.7:0.4:0.4, and then appropriate amounts of DMF and DIPEA are added to dissolve the solid drug, first react in an ice bath for 30 minutes, and then stir the reaction at room temperature for 4 hours. After the reaction is completed, the reaction solution is extracted, washed, salted out, and dried to obtain a crude product solution, and then the crude reaction solution is concentrated and purified to obtain TK-OAm.

[0060] Furthermore, in the step (3), the synthesis method of the glutamate dendritic lipopeptide molecule EDL is as follows:

[0061] 1) In an ice bath and under nitrogen protection, the above raw materials are added to a reaction device according to the molar ratio of Fmoc-L-Glu-OH, H-Glu(OtBu)-OtBu·HCl, HOBT, HBTU, and DIPEA being 1:2.4:2.5:2.5:7.5, respectively, and DMF and DIPEA are added to dissolve the solid drug, and the reaction is first carried out in an ice bath for 30 minutes, and then stirred at room temperature for 24 hours. After the reaction is completed, the reaction solution is extracted, washed, salted out, and dried to obtain a crude product solution, and then the crude reaction solution is concentrated and purified to obtain Compound 6;

[0062] 2) Place Compoud 6 in a reaction device, slowly add an appropriate amount of dichloromethane under nitrogen protection, slowly add a mixed solution of TFA and DCM in a volume ratio of 1:1 and a small amount of triethylsilane after the solid is dissolved, stir and react in an ice bath under nitrogen protection for 30 minutes, and continue to stir and react at room temperature for 4-6 hours; monitor the reaction progress by spot plate, after the reaction is completed, evaporate and concentrate the reaction solution under reduced pressure, spin dry, wash, and vacuum dry for 24 hours to obtain Compoud 7; wherein, the weight volume ratio of Compoud 6 to the mixed solution of TFA and DCM is: 2.5g:4mL;

[0063] 3) Adding Compoud 7, H-Glu(OtBu)-OtBu·HCl, HOBT, HBTU and DIPEA in a molar ratio of 1:4.8:5:5:15 respectively, using DMF as the reaction solvent, and the rest of the synthesis process is the same as the above step 1) to obtain Compoud 8;

[0064] 4) Using Compoud 8 as a raw material to prepare Compoud 9, the synthesis process is the same as the above step 2);

[0065] 5) Adding Compoud 9, H-Glu(OtBu)-OtBu·HCl, HOBT, HBTU and DIPEA in a molar ratio of 1:10:10:10:36, the reaction solvent is DMF, and the rest of the synthesis process is the same as the above step 1) to obtain Compoud 10;

[0066] 6) Take Compoud 10 in a reaction device, slowly add DMF under nitrogen protection, and slowly add a mixed solution of piperidine and DMF with a volume ratio of 1:4 after the solid is dissolved; stir the reaction in an ice bath under nitrogen protection for 30 minutes, and continue to stir the reaction at room temperature for 6-8 hours; after the reaction is completed, transfer the reaction solution to another reaction device, add a small amount of anhydrous ethanol, and evaporate and concentrate under reduced pressure, repeat this step to remove piperidine until there is no residual piperidine in the spot plate detection, and vacuum dry for 24 hours to obtain Compoud 11; wherein, the weight volume ratio of Compoud 10 to the mixed solution of piperidine and DMF is: 1.5g:8mL;

[0067] 7) Adding the materials according to the molar ratio of Compoud 11, oleic acid, HOBT, HBTU and DIPEA of 1:1.8:2:2:3.7, the reaction solvent is DMF, and the rest of the synthesis process is the same as the above step 1) to obtain Compoud 12;

[0068] 8) EDL was prepared using Compoud 12 as a raw material. The synthesis process of EDL was the same as the above step 2).

[0069] In the third aspect of the present invention, there is provided the use of the bifunctional dendritic lipopeptide nanomicelles as described in the first aspect or the bifunctional dendritic lipopeptide nanomicelles prepared by the preparation method described in the second aspect in the preparation of an immune cell autophagy inducer.

[0070] The present invention has the following technical effects:

[0071] 1) The bifunctional dendritic lipopeptide nanomicelles prepared by the present invention are prepared into nanomicelles by a solvent injection method and utilizing the amphiphilicity of the dendritic lipopeptide. The structure of the dendritic lipopeptide is similar to that of a surfactant. The hydrophilic lysine sequence constitutes the head, which can form a stable intramolecular hydrogen bond, thereby enhancing the stability of the formed vesicles. The hydrophobic alkyl chain serves as the tail, which together with the head constitutes a unique structure of the dendritic lipopeptide, has excellent water solubility, biocompatibility, and biodegradability, and has great application potential and prospects in drug delivery.

[0072] 2) The bifunctional dendritic lipopeptide nanomicelle of the present invention is a bifunctional nanomicelle based on dendritic lipopeptide molecules D -RNPs. In the inflammatory area, excessive production of ROS will lead to oxidative stress, and the autophagic activity of cells is often inhibited. Oxidative stress promotes inflammatory response, and the inhibition of cell autophagy may lead to the continuous accumulation of damaged substances in cells, further aggravating cell damage, inflammatory response and lipid peroxidation, and promoting the further development of inflammation. Bifunctional nanomicelles D-RNPs are ROS-responsive and can respond to changes in ROS levels at the lesion site, clear excess ROS, reduce oxidative stress and inflammatory responses, and activate autophagy and clear intracellular damaged substances by releasing D-lysine dendrimers and fourth-generation glutamate dendrimers, thereby achieving a therapeutic effect.

[0073] 3) The present invention creatively mixes two fourth-generation dendrimers (lysine and glutamic acid) and self-assembles them into dendritic lipopeptide nano-micelles. Under the background of the prior art, the hydrophobic long chain structure of the fourth-generation lysine dendrimers is creatively changed, and a self-synthesized ROS response key (TK) is added to make it low in toxicity and ROS responsive. In terms of activating autophagy, the expression of P63 and LC3 proteins was verified by immune protein experiments. Compared with the existing technology, the autophagy effect is better and has good ROS responsiveness. BRIEF DESCRIPTION OF THE DRAWINGS

[0074] Figure 1 Nanomicelle particle size and PDI diagram (Mean, n=3).

[0075] Figure 2 for L -G2K and D -Mass spectrum of G2K.

[0076] Figure 3 for L -G3K and D -Mass spectrum of G3K.

[0077] Figure 4 for L -G4K and D -Mass spectrum of G4K.

[0078] Figure 5 is the mass spectrum of TK.

[0079] Figure 6-1 This is the mass spectrum of TK-OAm.

[0080] Figure 6-2 for L -Mass spectrum of KRDL.

[0081] Figure 6-3 for D -Mass spectrum of KRDL.

[0082] Figure 7 for D -Mass spectrum of KNDL.

[0083] Figure 8 is the mass spectrum of EDL.

[0084] Fig. 9Chiral dendrimer G n CD spectrum of K.

[0085] Fig.10 This is a graph showing the protein adsorption levels after the nanomicelles were incubated with FBS for 2h and 4h.

[0086] Fig.11 The fluorescence intensity of the intracellular ROS probe after nanomicelles scavenged ROS, where **** indicates p < 0.0001, ns indicates p ≥ 0.05, n = 3.

[0087] Fig.12 The expression level and semi-quantitative analysis of autophagy marker proteins LC3 and p62 in foam cells after nanomicelle treatment, where **** indicates p<0.0001, ** indicates p<0.01, ns indicates p≥0.05, n=3. DETAILED DESCRIPTION

[0088] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments.

[0089] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0090] Among them: L-lysine methyl ester dihydrochloride (H-Lys-OMe·2HCl) was purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.; (S)-2,6-di-tert-butyloxycarbonylaminohexanoic acid (Boc-Lys(Boc)-OH) was purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.; D-lysine methyl ester dihydrochloride (DH-Lys-OMe·2HCl) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; N2,N6-bis(tert-butyloxycarbonyl)-D-lysine (Boc-D-Ly s(Boc)-OH), purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.; L-glutamic acid di-tert-butyl ester hydrochloride (H-Glu(OtBu)-OtBu·HCl), purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.; N-(9-fluorenylmethoxycarbonyl)-L-glutamic acid (Fmoc-L-Glu-OH), purchased from Beijing Bailingwei Technology Co., Ltd.; N-fluorenylmethoxycarbonyl-1,2-diaminoethane hydrochloride (Fmoc-ethylenediamine), purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.; 3- Mercaptopropionic acid was purchased from Shanghai Bidex Pharmaceutical Technology Co., Ltd.; triethylsilane was purchased from Shanghai Aladdin Biochemical Co., Ltd.; oleylamine (OAm) was purchased from Shanghai Aladdin Biochemical Co., Ltd.; oleic acid (OAc) was purchased from Shanghai Bidex Pharmaceutical Technology Co., Ltd.; 1-hydroxybenzotriazole (HOBt) was purchased from Shanghai Bidex Pharmaceutical Technology Co., Ltd.; benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) was purchased from Shanghai Bidex Pharmaceutical Technology Co., Ltd.; 1-ethyl Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) was purchased from Shanghai Aladdin Biochemical Co., Ltd.; N-hydroxysuccinimide (NHS) was purchased from Shanghai Aladdin Biochemical Co., Ltd.; phorbol 12-myristate 13-acetate (PMA) was purchased from Beyotime Biotechnology Co., Ltd.; lipopolysaccharide (LPS) (derived from Escherichia coli 055:B5) was purchased from Sigma-Aldrich; oxidized low-density lipoprotein (oxLDL) was purchased from Guangzhou Yiyuan Biotechnology Co., Ltd.

[0091] Example 1 Second Generation Chiral Dendrimers L -G2K and D -Synthesis of G2K

[0092] L -G2K, D -G2K mass spectrum Figure 2 , the synthetic route is as follows:

[0093]

[0094] LSynthesis of -G2K: Weigh H-Lys-OMe·2HCl 2.33g (10mmol), Boc-Lys(Boc)-OH 7.97g (23mmol), HOBT 4.05g (30mmol), HBTU 11.38g (30mmol), and DIPEA 10.45mL (60mmol). Add H-Lys-OMe·2HCl, Boc-Lys(Boc)-OH, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA in a molar ratio of 1:2:3:3:6, respectively, and the reaction solvent is 50mL DMF.

[0095] The above raw materials were added to a branched bottle under ice bath and nitrogen protection, and then appropriate amounts of DMF and DIPEA were added to dissolve the solid drug. The reaction was first reacted in an ice bath for 30 minutes, and then stirred at room temperature for 24 hours. After the reaction was completed, the reaction solution was extracted with ethyl acetate, and washed, salted out and dried with saturated NaHCO3, dilute hydrochloric acid, saturated NaCl and anhydrous Na2SO4 to obtain a crude product solution. The crude reaction solution was then concentrated and purified by thin layer chromatography, with the mobile phase being petroleum ether: ethyl acetate (1:1, V:V), to obtain L -G2K(Boc)4.

[0096] Weigh the above L -G2K(Boc)42.0g was placed in a three-necked flask, a magnetic particle was added, and the flask was sealed with a rubber stopper and placed in an ice bath. Under nitrogen protection, 6mL DCM was slowly added to dissolve it, and then 6mL TFA was slowly added. The reaction was stirred in an ice bath for 30 minutes, and the reaction was continued at room temperature for 6 hours. After the reaction was completed, the reaction solution was evaporated and concentrated to dryness under reduced pressure, and pre-cooled anhydrous ether was added to wash until white, and vacuum dried for 24 hours to obtain L -G2K was a white solid (0.96 g), with a yield of 86.9%.

[0097] DSynthesis of -G2K: Weigh DH-Lys-OMe·2HCl 2.33g (10mmol), Boc-D-Lys(Boc)-OH 7.97g (23mmol), HOBT 4.05g (30mmol), HBTU 11.38g (30mmol), and DIPEA 10.45 mL (60mmol). Add DH-Lys-OMe·2HCl, Boc-Lys(Boc)-OH, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA in a molar ratio of 1:2:3:3:6, and the reaction solvent is 50mL DMF. The rest of the synthesis process is the same as above. L -G2K, with a yield of 88.2%.

[0098] L -G2K and D -The mass spectrometry results of G2K are as follows Figure 2 As shown, MS (ESI) m / z: 417.4 [M+H] + The theoretical molecular weights of the two are consistent with the calculated molecular weights. The results of H NMR spectra show that L -G2K 1 H-NMR (300MHz, D2O): δ4.39 (dd, J=8.6,5.6Hz,1H),3.99 (q, J=6.2Hz,1H),3.88 (t, J=6.7Hz,1H),3.71 (s,3H),3.18 (t, J=7.2Hz,2H),2.96 (q, J=7.0Hz,4H),1.98–1.03 (m,22H). The characteristic peaks were correctly assigned. D -G2K 1 H-NMR (300MHz, D2O): δ4.38 (dd, J = 8.6, 5.6Hz, 1H), 3.99 (t, J = 6.4Hz, 1H), 3.87 (t, J = 6.7Hz, 1H), 3.70 (s, 3H), 3.23–3.13 (m, 2H), 2.95 (q, J = 6.5Hz, 4H), 1.95–1.08 (m, 22H). The peaks are correctly assigned. The results of mass spectrometry and H-NMR spectra prove that L -G2K and D -G2K has been successfully synthesized.

[0099] Example 2: Third Generation Chiral Dendrimers L -G3K and D -Synthesis of G3K

[0100] L -G3K, D-The mass spectrum of G3K is as Figure 3 , the synthetic route is as follows:

[0101]

[0102] L -G3K synthesis: weigh L -G2K 1.22 g (2.93 mmol), Boc-Lys(Boc)-OH 4.67 g (13.48 mmol), HOBT 2.38 g (17.58 mmol), HBTU 6.67 g (17.58 mmol), DIPEA 4.54 mL (35.16 mmol). L -G2K, Boc-Lys(Boc)-OH, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA were added in a molar ratio of 1:4:5:5:11, respectively, and the reaction solvent was 70 mL of DMF.

[0103] Add the above raw materials into a branched bottle under the protection of nitrogen in an ice bath, and then add appropriate amounts of DMF and DIPEA to dissolve the solid drug. First react in an ice bath for 30 minutes, and then stir the reaction at room temperature for 24 hours. After the reaction is completed, the reaction solution is extracted with ethyl acetate, and washed, salted out and dried with saturated NaHCO3, dilute hydrochloric acid, saturated NaCl and anhydrous Na2SO4 to obtain a crude product solution. After filtration, the organic phase is evaporated and concentrated under reduced pressure, and then recrystallized with ethyl acetate. Filter the crystals and wash with cold ethyl acetate. After filtration to dryness, vacuum dry for 24 hours. Obtain L -G3K(Boc)8 white solid.

[0104] Weigh the above L -G3K(Boc)82.0g was placed in a three-necked flask, a magnetic bar was added and the three-necked flask was sealed with a rubber stopper, and the three-necked flask was placed in an ice bath. Under nitrogen protection, 14mL of a mixed solvent of TFA and DCM (1:1, V:V) was slowly added to the three-necked flask. Under nitrogen protection, the reaction was stirred in an ice bath for 30 minutes, and the reaction was continued to be stirred at room temperature for 6 hours. After the reaction was completed, the reaction solution was evaporated and concentrated under reduced pressure and dried, and then pre-cooled anhydrous ether was added to wash until a white solid was obtained, and vacuum dried for 24 hours. L -G3K was a white solid (0.97 g), with a yield of 90.7%.

[0105] D -G3K synthesis: weigh D-G2K 1.22 g (2.93 mmol), Boc-D-Lys(Boc)-OH 4.67 g (13.48 mmol), HOBT 2.38 g (17.58 mmol), HBTU 6.67 g (17.58 mmol), DIPEA 4.54 mL (35.16 mmol). D -G2K, Boc-D-Lys(Boc)-OH, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA were added in a molar ratio of 1:4:5:5:11, and the reaction solvent was DMF. The rest of the synthesis process was the same as above L -G3K, yield 94.0%.

[0106] L -G3K and D -The mass spectrometry results of G3K are as follows Figure 3 As shown, MS (ESI) m / z: 929.0 [M] + The theoretical molecular weights of the two are consistent with the calculated molecular weights. The results of H NMR spectra show that L -G3K 1 H-NMR (300MHz, D2O): δ4.33–4.11 (m, 3H), 4.02–3.83 (m, 4H), 3.70 (s, 3H), 3.51 (q, J=7.1Hz, 4H), 3.27–3.05 (m, 6H), 2.95 (q, J=7.1Hz, 8H), 1.86–1.09 (m, 46H). The characteristic peaks were correctly assigned. D -G3K 1 H-NMR (300MHz, D2O): δ4.32–4.13 (m, 3H), 4.02–3.84 (m, 4H), 3.70 (s, 3H), 3.51 (q, J = 7.1 Hz, 4H), 3.13 (dt, J = 21.5, 6.9 Hz, 6H), 2.99–2.92 (m, 8H), 1.86–1.10 (m, 46H), the peaks are correctly assigned. The results of mass spectrometry and nuclear magnetic resonance hydrogen spectrum prove L -G3K and D -G3K has been successfully synthesized.

[0107] Example 3: Fourth Generation Chiral Dendrimers L -G4K and D -G4K Synthesis

[0108] L -G4K and D -The mass spectrum of G4K is as Figure 4 , the synthetic route is as follows:

[0109]

[0110] L -G4K synthesis: weigh L -G3K 1.5 g (1.61 mmol), Boc-Lys(Boc)-OH 5.82 g (16.8 mmol), HOBT 2.61 g (19.32 mmol), HBTU 7.32 g (19.32 mmol), DIPEA 6.24 mL (48.3 mmol). L -G3K, Boc-Lys(Boc)-OH, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA were added in a molar ratio of 1:10:12:12:30, respectively, and the reaction solvent was 70 mL of DMF.

[0111] Add the above raw materials into a three-necked flask under the protection of nitrogen in an ice bath, and then add appropriate amounts of DMF and DIPEA to dissolve the solid drug. First react in an ice bath for 30 minutes, and then stir and react at room temperature for 36 hours. After the reaction is completed, the reaction solution is extracted with ethyl acetate, and washed, salted out and dried with saturated NaHCO3, dilute hydrochloric acid, saturated NaCl and anhydrous Na2SO4 to obtain a crude product solution. After filtration, the organic phase is concentrated by vacuum evaporation and then recrystallized with ethyl acetate. Filter the crystals and wash with cold ethyl acetate. After filtration to dryness, vacuum dry for 24 hours. L -G4K(Boc) 16 White solid.

[0112] Weigh the above L -G4K(Boc) 16 2.0g was placed in a three-necked flask, a magnetic rod was added, and the mixture was sealed with a rubber stopper and placed in an ice bath. Under nitrogen protection, 16mL of a mixed solvent of TFA and DCM (1:1, V:V) was slowly added to the three-necked flask. Under nitrogen protection, the reaction was stirred in an ice bath for 30 minutes, and the reaction was continued to be stirred at room temperature for 7 hours. After the reaction was completed, the reaction solution was evaporated and concentrated to dryness under reduced pressure, and then pre-cooled anhydrous ether was added to wash until a white solid was obtained, and vacuum dried for 24 hours. L -G4K was a white solid (1.03 g), with a yield of 89.1%.

[0113] D -G4K synthesis: weigh D-G3K 1.5 g (1.61 mmol), Boc-D-Lys(Boc)-OH 5.82 g (16.8 mmol), HOBT 2.61 g (19.32 mmol), HBTU 7.32 g (19.32 mmol), DIPEA 6.24 mL (48.3 mmol). D -G3K, Boc-D-Lys(Boc)-OH, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA were added in a molar ratio of 1:10:12:12:30, and the reaction solvent was DMF. The rest of the synthesis process was the same as above L -G4K, with a yield of 91.3%.

[0114] L -G4K and D -The mass spectrometry results of G4K are as follows Figure 4 As shown, MS (ESI) m / z: 1977.79 [M+Na] + The theoretical molecular weights of the two are consistent with the calculated molecular weights. The results of H NMR spectra show that L -G4K 1 H-NMR (300MHz, D2O): δ4.28–4.10 (m, 7H), 3.97 (t, J = 6.6 Hz, 4H), 3.86 (t, J = 6.6 Hz, 4H), 3.68 (s, 3H), 3.50 (q, J = 7.1 Hz, 4H), 3.30–3.06 (m, 18H), 2.94 (q, J = 6.9 Hz, 20H), 1.74–1.08 (m, 94H). The characteristic peaks were correctly assigned. D -G4K 1 H-NMR (300MHz, D2O): δ4.35–4.10 (m, 7H), 3.99 (t, J = 6.6Hz, 4H), 3.93–3.86 (m, 4H), 3.70 (s, 3H), 3.53 (d, J = 7.1Hz, 4H), 3.24 (d, J = 43.1Hz, 18H), 2.97 (d, J = 7.8Hz, 20H), 1.73–1.12 (m, 94H), the peaks are correctly assigned. The results of mass spectrometry and nuclear magnetic resonance hydrogen spectrum prove L -G4K and D -G4K has been successfully synthesized.

[0115] Example 4 Synthesis of ROS-responsive bond thioketal TK

[0116] The mass spectrum of TK Figure 5 , the synthetic route is as follows:

[0117]

[0118] Anhydrous 3-mercaptopropionic acid (108.02 mmol) and anhydrous acetone (49.10 mmol) were placed in a three-necked flask and stirred, and a catalytic amount of TFA was added. The reaction was stirred at room temperature for 6 hours. At the end of the reaction, a white solid was precipitated. The white solid was filtered and washed alternately with cold n-hexane and cold deionized water for 5 times each. The residual 3-mercaptopropionic acid and acetone were removed by using the water-soluble properties of 3-mercaptopropionic acid and acetone. After vacuum drying for 24 hours, 10.32 g of TK white solid was obtained, with a yield of 71.9%.

[0119] Example 5 ROS-responsive dendritic lipopeptide L -KRDL and D -Synthesis of KRDL

[0120]

[0121] First, a carbon chain containing a TK bond, TK-OAm, was synthesized and used as the hydrophobic part of the ROS-responsive dendritic lipopeptide KRDL. Its mass spectrum is shown in Figure 6-1 The synthesis route is as follows: weigh TK 1.52g (5.39mmol), OAm 0.48g (1.80mmol), EDCI 0.41g (2.16mmol), NHS 0.25g (2.16mmol). TK, OAm, condensation agent [carbodiimide hydrochloride (EDCI)], NHS were added in a molar ratio of 1:2.7:0.4:0.4, respectively, and the reaction solvent was 30mL DMF.

[0122] The above raw materials were added to a three-necked flask under the protection of nitrogen in an ice bath, and then appropriate amounts of DMF and DIPEA were added to dissolve the solid drug. The reaction was first carried out in an ice bath for 30 minutes, and then stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was extracted with ethyl acetate, and washed, salted out and dried with saturated NaHCO3, dilute hydrochloric acid, saturated NaCl, and anhydrous Na2SO4 to obtain a crude product solution. The crude reaction solution was then concentrated and purified by thin layer chromatography, with the mobile phase being dichloromethane: methanol (45:1, V:V), to obtain 384.5 mg of TK-OAm with a yield of 42.7%.

[0123] L-type and D-type ROS-responsive dendritic lipopeptides L -KRDL, D -The mass spectrum of KRDL is as follows Figure 6-2 , 6-3, the specific synthetic route is as follows:

[0124]

[0125] L -Synthesis of KRDL:

[0126] (1) Weigh L -G4K(Boc) 16 0.5g (0.14mmol) was placed in an eggplant-shaped flask, a magnetic rod was added and the three-necked flask was placed in an ice bath. 25mL of sodium hydroxide methanol solution (1mol / L) was added to the eggplant-shaped flask and the reaction was carried out in an ice bath for 8h. After the reaction was completed, the pH of the reaction solution was adjusted to 3-4 with hydrochloric acid solution (1mol / L), and the reaction solution was extracted with ethyl acetate 3 times, the organic phase was collected, and anhydrous Na2SO4 was added to dry. After suction filtration, the solvent was removed by evaporation and concentration under reduced pressure, and vacuum dried for 24h. 0.385g of Compoud 1 as a white solid was obtained with a yield of 77.3%.

[0127] (2) Weigh 0.04 g (0.142 mmol) of Fmoc-ethylenediamine, 0.024 g (0.177 mmol) of HOBT, 0.067 g (0.177 mmol) of HBTU, and 0.2 mL (1.15 mmol) of DIPEA. Add Fmoc-ethylenediamine, Compoud 1, condensing agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA in a molar ratio of 1:1:1.2:1.2:8. Add the above raw materials into a three-necked flask under the protection of nitrogen in an ice bath, and then add 35 mL of DMF and DIPEA to dissolve the solid drug. First, react in an ice bath for 30 minutes, and then stir and react at room temperature. After the reaction is completed, the reaction solution is extracted with ethyl acetate, and washed with saturated NaHCO3, dilute hydrochloric acid, saturated NaCl, and anhydrous Na2SO4, salted out, and dried to obtain a crude product solution. After filtration, the organic phase is evaporated and concentrated under reduced pressure, and then recrystallized with ethyl acetate. Filter the crystals and wash with cold ethyl acetate, filter until dry, and then vacuum dry for 24 hours. L -Compoud 2 was a white solid (0.345 g), with a yield of 64.2%.

[0128] (3) Precision weighing L -Compoud 20.22g (0.231mmol) was placed in a three-necked flask, a magnetic bar was added and the three-necked flask was sealed with a rubber stopper, and the three-necked flask was placed in an ice bath. Under nitrogen protection, 5mL of a mixed solvent of piperidine and DMF (1:4, V:V) was slowly added. Under nitrogen protection, the reaction was stirred in an ice bath for 30 minutes, and the reaction was continued to be stirred at room temperature for 6 hours. After the reaction was completed, the reaction solution was transferred to an eggplant-shaped bottle. Anhydrous ethanol was added and evaporated under reduced pressure to concentrate, and the operation was repeated until there was no point of piperidine when the plate was dotted. After the piperidine was cleaned, it was evaporated under reduced pressure and concentrated to dryness, and vacuum dried for 24 hours. ObtainedL -Compoud 3 was a white solid (0.157 g), with a yield of 75.7%.

[0129] (4) Weigh L -Compoud 30.208 g (0.058 mmol), TK-OAm 0.038 g (0.0754 mmol), HOBT 0.012 g (0.087 mmol), HBTU 0.033 g (0.087 mmol), DIPEA 0.1 mL (0.58 mmol). L -Compoud, TK-OAm, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA were added in a molar ratio of 1:1.2:1.3:1.3:10. The above raw materials were added to a three-necked flask under ice bath and nitrogen protection, and 30mL DMF and DIPEA were added to dissolve the solid drug. The reaction was first reacted in an ice bath for 30 minutes, and then stirred at room temperature. After the reaction was completed, the reaction solution was extracted with ethyl acetate, and washed, salted out, and dried with saturated NaHCO3, dilute hydrochloric acid, saturated NaCl, and anhydrous Na2SO4 to obtain a crude product solution. After filtration, the organic phase was evaporated and concentrated under reduced pressure, and then recrystallized with ethyl acetate. Filter the crystals and wash with cold ethyl acetate. After filtration to dryness, vacuum dry for 24 hours. 0.169g of L-Compoud 4 white solid was obtained with a yield of 81.6%.

[0130] (5) Weigh L -Compoud 40.2g (0.05mmol) was placed in a three-necked flask, a magnetic particle was added, and the mixture was sealed with a rubber stopper and placed in an ice bath. Under nitrogen protection, 8mL of a mixed solution of TFA and DCM (1:3, V:V) was slowly added to the three-necked flask. Under nitrogen protection, the reaction was stirred in an ice bath for 30 minutes, and the reaction was continued to be stirred at room temperature for 7 hours. After the reaction was completed, the reaction solution was evaporated and concentrated to dryness under reduced pressure, and then pre-cooled anhydrous ether was added to wash until white, and vacuum dried for 24 hours. L -KRDL was white solid 0.2 g (0.05 mmol).

[0131] D -Synthesis of KRDL:

[0132] (1) Weigh D -G4K(Boc) 160.5g (0.14mmol) was placed in an eggplant-shaped flask, a magnetic rod was added and the three-necked flask was placed in an ice bath. 25mL of sodium hydroxide methanol solution (1mol / L) was added to the eggplant-shaped flask and the reaction was carried out in an ice bath for 8h. After the reaction was completed, the pH of the reaction solution was adjusted to 3-4 with hydrochloric acid solution (1mol / L), and the reaction solution was extracted with ethyl acetate 3 times, the organic phase was collected, and anhydrous Na2SO4 was added to dry it. After filtration, the solvent was evaporated and concentrated under reduced pressure, and vacuum dried for 24h. D -Compoud 1 white solid 0.399 g, yield 80.1%.

[0133] (2)-(5) steps are the same as L -Synthesis of KRDL.

[0134] Comparative Example 1: No ROS-responsive dendritic lipopeptide D -Synthesis of KNDL

[0135] Synthesis of ROS-insensitive dendritic lipopeptides without TK bonds D -KNDL, a control lipopeptide used in the subsequent ROS response performance investigation. D -The mass spectrum of KNDL is as follows Figure 7 , the synthetic route is as follows:

[0136]

[0137] Weigh 10.5g (0.28mmol) of Compoud, 0.057g (0.42mmol) of HOBT, 0.159g (0.42mmol) of HBTU, and 0.2mL (1.15mmol) of DIPEA. Add the materials according to the molar ratio of Compoud, oleylamine, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA, respectively, at 1:2:1.5:1.5:4. Add the above raw materials into a three-necked flask under the protection of nitrogen in an ice bath, add 0.15g (0.56mmol) of oleylamine, dissolve the solid drug with 40mL of DMF and DIPEA, react in an ice bath for 30min, and then stir and react at room temperature for 24-30h. After the reaction is completed, the reaction solution is extracted with ethyl acetate, and washed with saturated NaHCO3, dilute hydrochloric acid, saturated NaCl, and anhydrous Na2SO4, salted out, and dried to obtain a crude product solution. After suction filtration, the organic phase is evaporated and concentrated under reduced pressure, and then recrystallized with ethyl acetate. The crystals are filtered and washed with cold ethyl acetate, filtered to dryness, and then vacuum dried for 24 hours. Compoud 5 is obtained as a white solid.

[0138] Weigh 50.5g (0.13mmol) of Compoud into a three-necked flask, add a magnetic bar and seal the three-necked flask with a rubber stopper, and place the three-necked flask in an ice bath. Under nitrogen protection, slowly add 6mL of a mixed solvent of TFA and DCM (1:1, V:V). Under nitrogen protection, stir the reaction in an ice bath for 30 minutes, and continue to stir the reaction at room temperature for 8 hours. After the reaction is completed, evaporate the reaction solution under reduced pressure and concentrate it to dryness, then add pre-cooled anhydrous ether to wash it until it turns white, and vacuum dry it for 24 hours. D -KRDL was a white solid (0.192 g), with a yield of 66.9%.

[0139] Example 6 Synthesis of Dendritic Lipopeptide EDL with Glutamic Acid as Basic Structural Unit

[0140] Dendritic molecules with glutamic acid as the basic structural unit were synthesized by amide condensation reaction and OtBu removal reaction, which served as the hydrophilic head of EDL. The Fmoc protecting group was further removed from the dendritic molecule to expose the amino group. Oleic acid (OAc) was used as the hydrophobic tail of EDL, and the carboxyl group on oleylamine was condensed with the amino group on the dendritic molecule through amide condensation reaction to obtain the dendritic lipopeptide EDL. The mass spectrum of EDL is shown in Figure 8 , the synthetic route is as follows:

[0141]

[0142] (1) Weigh 2.58 g (7 mmol) of Fmoc-L-Glu-OH, 4.35 g (16.8 mmol) of H-Glu(OtBu)-OtBu·HCl, 2.36 g (17.5 mmol) of HOBT, 6.64 g (17.5 mmol) of HBTU, and 9.2 mL (52.5 mmol) of DIPEA. Add Fmoc-L-Glu-OH, H-Glu(OtBu)-OtBu·HCl, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA in a molar ratio of 1:2.4:2.5:2.5:7.5, respectively, and the reaction solvent is 50 mL of DMF.

[0143] The above raw materials were added to a three-necked flask under ice bath and nitrogen protection, and 50 mL of DMF and DIPEA were added to dissolve the solid drug. The reaction was first carried out in an ice bath for 30 minutes, and then stirred at room temperature for 24 hours. After the reaction, the reaction solution was extracted with ethyl acetate, and washed, salted out and dried with saturated NaHCO3, dilute hydrochloric acid, saturated NaCl and anhydrous MgSO4 to obtain a crude product solution. The crude reaction solution was then concentrated and purified by thin layer chromatography, with the mobile phase being petroleum ether: ethyl acetate (2:1, V:V) to obtain Compoud6.

[0144] (2) Weigh 2.5 g (2.94 mmol) of Compoud 6 into a three-necked flask. Under nitrogen protection, slowly add an appropriate amount of dichloromethane (DCM). After the solid in the three-necked flask is dissolved, slowly add 4 mL of a mixed solution of TFA and DCM (1:1, V:V) and a small amount of triethylsilane. Under nitrogen protection, stir the reaction in an ice bath for 30 min, and continue to stir the reaction at room temperature for 6 h. Monitor the reaction progress by spotting. After the reaction is completed, evaporate the reaction solution under reduced pressure and concentrate it to dryness, then add pre-cooled anhydrous ether to wash it until it turns white, and vacuum dry it for 24 h. Obtain 1.47 g of Compoud 7 as a white solid.

[0145] (3) Weigh 1.63 g (2.6 mmol) of Compoud 7, 3.70 g (12.5 mmol) of H-Glu(OtBu)-OtBu·HCl, 1.76 g (13.0 mmol) of HOBT, 4.94 g (13.0 mmol) of HBTU, and 6.8 mL (39.1 mmol) of DIPEA. Add Compoud 7, H-Glu(OtBu)-OtBu·HCl, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA in a molar ratio of 1:4.8:5:5:15, respectively, and the reaction solvent is 50 mL of DMF. The rest of the synthesis process is the same as above (1), and the mobile phase is petroleum ether:ethyl acetate (1:1.5, V:V) to obtain Compoud 8.

[0146] (4) The synthesis process of Compound 9 is the same as that of (2) above.

[0147] (5) Weigh 1.5 g (1.31 mmol) of Compoud 9, 3.88 g (13.11 mmol) of H-Glu(OtBu)-OtBu·HCl, 1.77 g (13.1 mmol) of HOBT, 4.97 g (13.1 mmol) of HBTU, and 8.2 mL (47.16 mmol) of DIPEA. Add Compoud 9, H-Glu(OtBu)-OtBu·HCl, condensation agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA in a molar ratio of 1:10:10:10:36, respectively, and the reaction solvent is 55 mL of DMF. The rest of the synthesis process is the same as above (1), and the mobile phase is dichloromethane:methanol (35:1, V:V) to obtain Compoud 10.

[0148] (6) Weigh 1.5 g (0.49 mmol) of Compoud 10 into a three-necked flask. Under nitrogen protection, slowly add 2 mL of DMF. After the solid in the three-necked flask is dissolved, slowly add a mixed solution of 2 mL of piperidine and 6 mL of DMF (1:4, V:V). Under nitrogen protection, stir the reaction in an ice bath for 30 min, and continue to stir the reaction at room temperature for 8 h. After the reaction is completed, transfer the reaction solution to an eggplant-shaped bottle, add a small amount of anhydrous ethanol, and evaporate and concentrate under reduced pressure. Repeat this step to remove piperidine until there is no residual piperidine by spot plate detection. Vacuum dry for 24 h to obtain Compoud 11 as a white solid.

[0149] (7) Weigh 1.0 g (0.35 mmol) of Compoud 11, 0.2 mL (0.63 mmol) of oleic acid, 0.095 g (0.7 mmol) of HOBT, 0.265 g (0.7 mmol) of HBTU, and 0.25 mL (1.31 mmol) of DIPEA. Add Compoud 11, oleic acid, condensing agent [equimolar 1-hydroxybenzotriazole (HOBT) and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU)], and DIPEA in a molar ratio of 1:1.8:2:2:3.7, respectively, and the reaction solvent is 50 mL of DMF. The rest of the synthesis process is the same as above (1), and the mobile phase is dichloromethane:methanol (25:1, V:V) to obtain 0.68 g of white solid Compoud 12 with a yield of 62.4%.

[0150] (8) The synthesis process of EDL was the same as above (2) with a yield of 76.7%.

[0151] Example 7 Dendrimer G n Verification of K chirality

[0152] The secondary structure and chirality of chiral dendrimer peptides were analyzed by circular dichroism spectrometry. L -G1K(H-LysOMe·2HCl), D -G1K(DH-Lys-OMe·2HCl), L -G2K, D -G2K, L -G3K, D -G3K, L -G4K and D -G4K was prepared as a solution at a concentration of 1.5 mg / mL and measured in the wavelength range of 190 to 250 nm. Fig. 9 As shown, the results show that the CD spectra of the D-type and L-type dendrimer GnK exhibit perfect mirror symmetry in the detection range of 190nm to 250nm wavelength, proving that the two chiral dendrimers are exact enantiomers.

[0153] Example 8 Preparation of Nanomicelles by Solvent Injection Method

[0154] Weigh 5 mg D -KRDL, 5mg L -KRDL, 4.44mg D -KNDL, respectively, mixed with 4.5 mg EDL (1:1, mol:mol). Dissolved in a mixed solution of 50 μL of anhydrous ethanol and tetrahydrofuran (1:1, V:V), and uniformly added dropwise to a 1 mL PBS solution under rapid stirring, and continued stirring until the anhydrous ethanol and tetrahydrofuran were completely volatilized to form nanomicelles. D -RNPs, L -RNPs, D -NNPs.

[0155] PBS formula: NaCl 8g, KCl 0.2g, KH2PO4 0.2g, Na2HPO4.12H2O 2.56g dissolved in 1000ml distilled water, PH 7.2-7.4, 103kpa, sterilize for 15min, store at 4℃.

[0156] like Figure 1 , the solvent injection method was used to prepare micelles, and the corresponding average particle sizes were reduced to 179.5nm, 172.0nm and 138.1nm, respectively, which shows that the solvent injection method can prepare nanomicelles with smaller particle sizes. The reduction in particle size may be attributed to the influence of the rapid dilution process in the solvent injection method, which reduces the aggregation tendency of amphiphilic molecules and promotes the formation of smaller micelles. The polydispersity index (PDI) is a parameter to measure the uniformity of the particle size of nanomicelles. The smaller the PDI value, the more uniform the particle size distribution. Figure 1As shown, the corresponding PDIs are 0.2070, 0.2017 and 0.2387 respectively. These data show that D -RNPs, L -RNPs, D -NNPs showed lower PDI, i.e. better particle size uniformity.

[0157] Example 9 Test of the anti-protein adsorption performance of nanomicelles

[0158] In this experiment, bovine serum (FBS) was used as a model protein, and the anti-protein adsorption ability of nanogel was determined by ultraviolet absorption spectroscopy. D -RNPs, L -RNPs, D -NNPs solution (0.1, 0.5, 1 mg / mL) was mixed with 5% FBS solution and incubated on a shaker at 37°C. At 2h and 4h, aliquots of the mixture were taken and centrifuged at 8000rpm for 10min. The supernatant was aspirated and the absorbance at 275nm was measured using a UV-visible spectrophotometer. The amount of protein adsorbed on the sample was calculated based on the FBS standard curve. Each sample in this experiment was measured 3 times in parallel (n=3). Fig.10 As shown, the data show that whether L -RNPs, D -NNPs or D -RNPs, after incubation with bovine serum albumin (FBS) for 2 and 4 h, the observed protein adsorption was relatively low, indicating that all tested nanomicelles have a certain ability to resist protein adsorption.

[0159] Example 10 Investigation of ROS scavenging ability of nanomicelles

[0160] The DCFH-DA fluorescent probe method was used to determine the intracellular ROS content. RAW 264.7 cells in the logarithmic growth phase were collected by centrifugation and the supernatant was discarded. 5 mL of fresh complete medium was added and the cells were gently resuspended by blowing. The evenly blown cell suspension was loaded onto a hemocytometer for counting and the cell concentration was adjusted to 1×10 5 The cell suspension was inoculated into a 12-well plate, 1 mL per well, and cultured in an incubator for 24 h to allow the cells to fully adhere to the wall. A blank control group, a drug-treated group, and a positive control group were set up. The blank group N-CTL was added with basal culture medium; the drug-treated group was added with 1 mL of 200 μM H2O2 D -RNPs, D -NNPs, L-RNPs solution (the final concentration of nanomicelles is 1 mg / mL); 1 mL of basal medium containing 200 μM H2O2 was added to the positive control group P-CTL. After continuing to culture for 30 minutes, the culture medium was aspirated and each well was washed 3 times with PBS buffer. 100 μL of DCFH-DA probe was added to each well. After culturing for 20 minutes, each well was washed 3 times with PBS buffer. 400 μL of PBS solution was added to each well, and the cells were gently blown with a pipette until the cells fell off. The cell suspension was collected in a centrifuge tube, and the cell suspension was gently blown to make the cells evenly dispersed. The fluorescence intensity of DCFH-DA (EX: 488 nm, EM: 525 nm) was measured by flow cytometry. Two replicate wells (n=3) were set for each sample in the experiment. Fig.11 , the results show L -RNPs, D Compared with the -RNPs group and the P-CTL group, the fluorescence intensity was significantly reduced, and there was no significant difference compared with the blank control group N-CTL without external H2O2. D The fluorescence intensity of the -NNPs group was similar to that of the P-CTL group, indicating that there was no ROS scavenging effect. L -RNPs, D -RNPs have strong ROS scavenging ability, while nanomicelles without ROS response bond TK D -NNPs do not have ROS scavenging ability.

[0161] Example 11 Investigation of the Effect of Nanomicelles on the Expression of Autophagy Marker Proteins

[0162] The changes in the expression of autophagy-related proteins p62 and LC3-II in cells were studied by Western blot, and the expression level differences of the detected proteins were quantitatively analyzed by grayscale determination to determine the abundance of autophagosomes in cells. THP-1 cells in the logarithmic growth phase were collected by centrifugation, and 5 mL of fresh complete medium was added after discarding the supernatant. The cells were gently resuspended by blowing. The evenly blown cell suspension was loaded onto a hemocytometer for counting, and the cell concentration was adjusted to 3×10 5PMA (10 mg / mL) and LPS (1 mg / mL) were added to make the final concentration of PMA to be 1 μg / mL and the final concentration of LPS to be 500 ng / mL. The above cell suspension containing PMA and LPS was inoculated into a 60 mm cell culture dish (5 mL of cell suspension per dish), and the culture dish with cells was placed in an incubator at 37°C and 5% CO2 for 12 hours until the cells adhered to the wall. The experiment set up a blank control group N-CTL, a drug-treated group, a Rapa control group and a model control group M-CTL. The culture fluid was aspirated and washed three times with RPMI-1640 medium. Fresh culture medium was added to the blank group N-CTL, and 5 mL of serum-free culture medium containing 50 μg / mL oxLDL was added to the other groups. After being placed in an incubator and cultured for 36 hours, 5 mL of fresh culture medium was added to the N-CTL group and the P-CTL group; 5 mL of 1 mg / mL was added to the drug-treated group. D -RNPs, D -NNPs, L -RNPs; 1mL of culture medium containing 100nM Rapa solution was added to the Rapa control group. After administration, the cells were placed in an incubator at 37°C and 5% CO2 for 24h. Proteins were extracted by lysis with RIPA lysis buffer, and the protein concentration was determined by BCA method. The content of each sample was calculated according to the measured absorbance. Proteins of each group were diluted to the same concentration with RIPA lysis buffer, and 5×SDS protein loading buffer was added at a ratio of 1:4, and heated for denaturation. Gel preparation, sample loading, electrophoresis, membrane transfer, blocking, incubation with primary and secondary antibodies, and development were performed. Fig.12 The results showed that LC3-II protein expression D The expression level of LC3-II in the -RNPs group was significantly higher than that in the Rapa group. D The expression level of LC3-II in the -NNPs group was slightly higher than that in the Rapa group. L -RNPs group had a lower expression level of LC3-II. D -RNPs group may have a stronger autophagy activation effect. In terms of p62 protein expression, D -RNPs group p62 expression level close to the level of Rapa, while D The p62 expression in the -NNPs group was significantly higher than that in the Rapa group, indicating D -RNPs group may have an autophagy activation effect similar to rapamycin, indicating D -NNPs may have blocked autophagy pathway or incomplete autophagy process. Combining the changes of LC3-II and p62, compared with the Rapa group, D -NNPs group may have similar autophagy activation effect, while D -RNPs group had a stronger autophagy activation effect. L-RNPs group had no ability to activate autophagy.

[0163] The above are only embodiments of the present invention, and are not intended to limit the patent scope of the present invention. Any equivalent transformations made using the contents of the present invention specification, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.

Claims

1. A bifunctional dendritic lipopeptide nanomicelle, characterized in that: The bifunctional dendritic lipopeptide nano-micelles are made of chiral ROS-responsive dendritic lipopeptide KRDL and glutamic acid dendritic lipopeptide molecule EDL as raw materials: The structural formula of KRDL is shown in Formula I: in: R1 is a dendrimer polypeptide composed of lysines in a certain ratio through amide bonds, and the structure of R1 is shown in Formula II: In formula II, n represents D-lysine, and a tree network is formed by amide bonds; R2 is a carbon chain C containing a TK bond 27 H 50 O2NS2: The structure of the EDL is shown in Formula III: in: R3 is a dendrimer polypeptide composed of glutamic acids in a certain ratio through amide bonds, and the structure of R3 is shown in Formula IV: In formula IV, n represents glutamic acid, and a tree network is formed by amide bonds; R4 is a carbon chain C 18 H 33 O.

2. The bifunctional dendritic lipopeptide nanomicelle according to claim 1, characterized in that: The dendritic lipopeptide nano-micelles are prepared by mixing chiral ROS-responsive dendritic lipopeptide KRDL and glutamic acid dendritic lipopeptide molecules EDL in an equimolar ratio and by a solvent injection method.

3. The method for preparing the bifunctional dendritic lipopeptide nanomicelles according to any one of claims 1 to 2, characterized in that: The steps include: (1) Synthetic G n K(n=2,3,4) Synthesis of chiral dendrimers G with different generations based on D-lysine as the basic structural unit n K(Boc)(n=2,3,4), and further remove the Boc protecting group to obtain the corresponding chiral dendrimer product G n K(n=2,3,4); (2) Synthesis of chiral ROS-responsive dendritic lipopeptide KRDL Based on the fourth generation chiral lysine molecule, a demethylation reaction was performed with a sodium hydroxide methanol solution (1 mol / L) to expose the carboxyl group, extracted with ethyl acetate, dried with anhydrous Na2SO4, evaporated and concentrated under reduced pressure to remove the solvent, and vacuum dried for 24 hours to obtain a series of intermediates, which were then joined with a hydrophobic long chain consisting of ROS-responsive bond ketalthiols and oleylamine to synthesize a chiral ROS-responsive dendritic lipopeptide. D -KRDL; (3) Synthesis of glutamate dendritic lipopeptide molecules EDL Synthesize dendrimers of different generations with glutamic acid as the basic structural unit. On the basis of the fourth-generation glutamic acid molecule, further remove the Fmoc protecting group and then connect the hydrophobic long chain composed of oleic acid to synthesize the glutamic acid dendrimer lipopeptide molecule EDL. (4) Preparation of Nanomicelles Will D -KRDL and EDL were mixed in a 1:1 molar ratio, added to a 1:1 volume ratio of anhydrous ethanol and tetrahydrofuran to fully dissolve them, and then added dropwise to a rapidly stirred PBS solution at a uniform speed, and stirred until the anhydrous ethanol and tetrahydrofuran were completely volatilized to form nanomicelles. D -RNPs.

4. The method for preparing the bifunctional dendritic lipopeptide nanomicelles according to claim 3, characterized in that: In the step (1), the second generation chiral dendrimer D -The synthesis method of G2K is as follows: 1) In an ice bath and under nitrogen protection, the above raw materials are added to a reaction device according to the molar ratio of DH-Lys-OMe·2HCl, Boc-Lys(Boc)-OH, HOBT, HBTU, and DIPEA being 1:2:3:3:6, and then appropriate amounts of DMF and DIPEA are added to dissolve the solid drug, and the reaction is first carried out in an ice bath for 30 minutes, and then stirred at room temperature for 24 hours. After the reaction is completed, the reaction solution is extracted, washed, salted out, and dried to obtain a crude product solution, and then the crude reaction solution is concentrated and purified to obtain D -G2K(Boc)4; 2) Take the above D -G2K(Boc)4 was placed in a reaction apparatus, and DCM was slowly added to dissolve it under nitrogen protection, and then TFA was slowly added. The reaction was stirred in an ice bath for 30 minutes, and the reaction was continued at room temperature for 3-6 hours. After the reaction was completed, the reaction solution was evaporated and concentrated to dryness under reduced pressure, washed, and vacuum dried for 24 hours to obtain D -G2K; D -The weight volume ratio of G2K(Boc)4, DCM and TFA is: 1 g: 3 mL: 3 mL.

5. The method for preparing the bifunctional dendritic lipopeptide nanomicelles according to claim 3, characterized in that: In the step (1), the third generation chiral dendrimer D The synthesis method of -G3K is as follows: 1) In an ice bath and under nitrogen protection, D -G2K, Boc-D-Lys(Boc)-OH, HOBT, HBTU, DIPEA in a molar ratio of 1:4:5:5:11, the above raw materials are added to a reaction device, and then appropriate amounts of DMF and DIPEA are added to dissolve the solid drug, first react in an ice bath for 30 minutes, and then react under stirring at room temperature for 24 hours; after the reaction is completed, the reaction solution is extracted, and washed, salted out, and dried to obtain a crude product solution, and the organic phase is concentrated by reduced pressure evaporation after suction filtration, and then recrystallized, filtered and crystallized, filtered to dryness, and vacuum dried for 24 hours to obtain D -G3K(Boc)8 white solid; 2) Weigh the above D -G3K(Boc)8 in a reaction device, under nitrogen protection, slowly add a mixed solvent of TFA and DCM to the above reaction device, under nitrogen protection, stir the reaction in an ice bath for 30 minutes, and continue to stir the reaction at room temperature for 4-6 hours; after the reaction is completed, evaporate the reaction solution under reduced pressure and concentrate it to dryness, wash it, and vacuum dry it for 24 hours to obtain D -G3K; among them D -The weight volume ratio of G3K(Boc)8, TFA and DCM is: 2g:7mL:7mL.

6. The method for preparing the bifunctional dendritic lipopeptide nanomicelles according to claim 3, characterized in that: In the step (1), the fourth generation chiral dendrimer D -The synthesis method of G4K is as follows: 1) In an ice bath and under nitrogen protection, D -G3K, Boc-D-Lys(Boc)-OH, HOBT, HBTU, DIPEA in a molar ratio of 1:10:12:12:30, add the above raw materials into a reaction device, add appropriate amounts of DMF and DIPEA to dissolve the solid drug, first react in an ice bath for 30 minutes, then stir and react at room temperature for 36 hours, after the reaction is completed, extract the reaction solution, wash, salt out, and dry to obtain a crude product solution, filter and concentrate the organic phase by reduced pressure evaporation, then recrystallize, filter and crystallize, filter to dryness, and then vacuum dry for 24 hours to obtain D -G4K(Boc) 16 ; 2) Weigh the above D -G4K(Boc) 16 In a reaction apparatus, under nitrogen protection, a mixed solvent of TFA and DCM was slowly added to the above reaction apparatus, and the reaction was stirred in an ice bath under nitrogen protection for 30 minutes, and the reaction was continued to be stirred at room temperature for 5-7 hours. After the reaction was completed, the reaction solution was evaporated and concentrated to dryness under reduced pressure, washed, and vacuum dried for 24 hours to obtain D -G4K; D -G4K(Boc) 16 , the weight volume ratio of TFA and DCM is: 1g:4mL:4mL.

7. The method for preparing bifunctional dendritic lipopeptide nanomicelles according to claim 3, characterized in that: In the step (2), the synthesis method of the chiral ROS-responsive dendritic lipopeptide KRDL is as follows: (1) Take D -G4K(Boc) 16 In the reaction apparatus, sodium hydroxide methanol solution was added and the reaction was carried out under ice bath for 8 hours. After the reaction was completed, the pH of the reaction solution was adjusted to 3-4 with hydrochloric acid solution, and the reaction solution was extracted with ethyl acetate 3 times. The organic phase was collected, anhydrous Na2SO4 was added for drying, and the solvent was removed by vacuum evaporation after filtration. The product was dried in vacuo for 24 hours to obtain D -Compoud 1; (2) In an ice bath and under nitrogen protection, according to Fmoc-ethylenediamine, D -Compoud 1, HOBT, HBTU and DIPEA have a molar ratio of 1:1:1.2:1.2:

8. The above raw materials are added to a reaction device, and DMF and DIPEA are added to dissolve the solid drug. The reaction is first carried out in an ice bath for 30 minutes, and then stirred at room temperature for reaction. After the reaction is completed, the reaction solution is extracted, washed, salted out, and dried to obtain a crude product solution. After suction filtration, the organic phase is evaporated and concentrated under reduced pressure, and then recrystallized. The crystals are suction filtered, and after suction filtration to dryness, vacuum drying is performed for 24 hours to obtain D -Compoud 2; (3) Take D -Compoud 2 was placed in a reaction device, and under nitrogen protection, a mixed solvent of piperidine and DMF with a volume ratio of 1:4 was slowly added. Under nitrogen protection, the mixture was stirred in an ice bath for 30 minutes, and the mixture was stirred at room temperature for 6 hours. After the reaction was completed, the reaction solution was transferred to another reaction device, anhydrous ethanol was added, and the mixture was evaporated and concentrated under reduced pressure. The operation was repeated until there was no piperidine on the plate. After the piperidine was cleaned, the mixture was evaporated and concentrated under reduced pressure and dried, and vacuum dried for 24 hours to obtain D -Compoud 3; among them, D -The weight volume ratio of Compoud 2 to the mixed solvent of piperidine and DMF is: 0.22 g: 5 mL; (4) Under ice bath and nitrogen protection, D -Compoud 3, TK-OAm, HOBT, HBTU, DIPEA in a molar ratio of 1:1.2:1.3:1.3:10, add the above raw materials into a reaction device, then add DMF and DIPEA to dissolve the solid drug, first react in an ice bath for 30 minutes, then stir and react at room temperature, after the reaction is completed, extract the reaction solution, wash, salt out, and dry to obtain a crude product solution; after suction filtration, evaporate and concentrate the organic phase under reduced pressure, then recrystallize, filter the crystals, filter to dryness, and vacuum dry for 24 hours to obtain D -Compoud4; (5) Take D -Compoud4 was placed in a reaction device, and under nitrogen protection, a mixed solution of TFA and DCM in a volume ratio of 1:3 was slowly added to the above reaction device. Under nitrogen protection, the reaction was stirred in an ice bath for 30 minutes, and the reaction was continued at room temperature for 6-8 hours. After the reaction was completed, the reaction solution was evaporated and concentrated to dryness under reduced pressure, washed, and vacuum dried for 24 hours to obtain D -KRDL; among them, D -The weight volume ratio of the mixed solution of Compoud 4 and TFA and DCM is: 0.2 g:8 mL.

8. The method for preparing the bifunctional dendritic lipopeptide nanomicelles according to claim 7, characterized in that: In the step (2), the method for synthesizing the carbon chain TK-OAm containing a TK bond is as follows: in an ice bath and under nitrogen protection, the above raw materials are added to a reaction device according to a molar ratio of TK, OAm, EDCI, and NHS of 1:2.7:0.4:0.4, and then appropriate amounts of DMF and DIPEA are added to dissolve the solid drug, first react in an ice bath for 30 minutes, and then stir the reaction at room temperature for 4 hours. After the reaction is completed, the reaction solution is extracted, washed, salted out, and dried to obtain a crude product solution, and then the crude reaction solution is concentrated and purified to obtain TK-OAm.

9. The method for preparing the bifunctional dendritic lipopeptide nanomicelles according to claim 3, characterized in that: In the step (3), the synthesis method of the glutamate dendritic lipopeptide molecule EDL is as follows: 1) In an ice bath and under nitrogen protection, the above raw materials were added into a reaction apparatus according to the molar ratio of Fmoc-L-Glu-OH, H-Glu(OtBu)-OtBu·HCl, HOBT, HBTU and DIPEA being 1:2.4:2.5:2.5:7.5 respectively, and DMF and DIPEA were added to dissolve the solid drug, and the reaction was first carried out in an ice bath for 30 minutes, and then stirred at room temperature for 24 hours. After the reaction was completed, the reaction solution was extracted, washed, salted out and dried to obtain a crude product solution, and then the crude reaction solution was concentrated and purified to obtain Compound 6; 2) Place Compoud 6 in a reaction device, slowly add an appropriate amount of dichloromethane under nitrogen protection, slowly add a mixed solution of TFA and DCM in a volume ratio of 1:1 and a small amount of triethylsilane after the solid is dissolved, stir and react in an ice bath under nitrogen protection for 30 minutes, and continue to stir and react at room temperature for 4-6 hours; monitor the reaction progress by spot plate, after the reaction is completed, evaporate and concentrate the reaction solution under reduced pressure, spin dry, wash, and vacuum dry for 24 hours to obtain Compoud 7; wherein, the weight volume ratio of Compoud 6 to the mixed solution of TFA and DCM is: 2.5g:4mL; 3) Adding Compoud 7, H-Glu(OtBu)-OtBu·HCl, HOBT, HBTU and DIPEA in a molar ratio of 1:4.8:5:5:15 respectively, using DMF as the reaction solvent, and the rest of the synthesis process is the same as the above step 1) to obtain Compoud 8; 4) Using Compoud 8 as a raw material to prepare Compoud 9, the synthesis process is the same as the above step 2); 5) Adding Compoud 9, H-Glu(OtBu)-OtBu·HCl, HOBT, HBTU and DIPEA in a molar ratio of 1:10:10:10:36, the reaction solvent is DMF, and the rest of the synthesis process is the same as the above step 1) to obtain Compoud 10; 6) Take Compoud 10 in a reaction device, slowly add DMF under nitrogen protection, and slowly add a mixed solution of piperidine and DMF with a volume ratio of 1:4 after the solid is dissolved; stir the reaction in an ice bath for 30 minutes under nitrogen protection, and continue to stir the reaction at room temperature for 6-8 hours; after the reaction is completed, transfer the reaction solution to another reaction device, add a small amount of anhydrous ethanol, and evaporate and concentrate under reduced pressure, repeat this step to remove piperidine until there is no residual piperidine in the spot plate detection, and vacuum dry for 24 hours to obtain Compoud 11; wherein, the weight volume ratio of Compoud 10 to the mixed solution of piperidine and DMF is: 1.5g:8mL; 7) Adding the materials according to the molar ratio of Compoud 11, oleic acid, HOBT, HBTU and DIPEA of 1:1.8:2:2:3.7, the reaction solvent is DMF, and the rest of the synthesis process is the same as the above step 1) to obtain Compoud 12; 8) EDL was prepared using Compoud 12 as a raw material. The synthesis process of EDL was the same as the above step 2).

10. Use of the bifunctional dendritic lipopeptide nanomicelles according to any one of claims 1 to 2 in the preparation of an immune cell autophagy inducer.

Citation Information

Patent Citations

  • Environmental response type peptide-containing dendrimer lipid material and preparation method and application thereof

    CN105056251A

  • Progressive-response nano-self-assembled dendritic prodrug and preparation method and application thereof

    CN106421806A

  • Application of chiral dendritic peptide macromolecule as autophagy-inducing peptide drug

    CN107261112A

  • Bufalin micelle nano-preparation and preparation method thereof

    CN108295030A

  • Amphiphilic peptide dendrimer for photodynamic / NO synergistic biofilm infection resistance and wound healing promotion and preparation method and application thereof

    CN113368236A